MedPath

Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry

Conditions
Coronary Artery Disease
Registration Number
NCT01325467
Lead Sponsor
BSP Biological Signal Processing Ltd.
Brief Summary

This will be a registry study that will enroll patients referred for an ECG treadmill test with nuclear myocardial perfusion imaging (MPI). The high frequency QRS (HFQRS) information will be recorded and analyzed automatically and simultaneous with the standard ECG signals by the HyperQ System. Results of subsequent tests performed on each patient will be collected and used to enhance the reliability of designating each patient as a CAD-negative (i.e., no significant coronary artery disease) or a CAD-positive (i.e., significant coronary artery disease).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
900
Inclusion Criteria
  • 18 years or older
  • Referred for exercise MPI due to suspected coronary artery disease
Exclusion Criteria
  • Acute Coronary Syndrome (Unstable angina/NSTEMI/STEMI)
  • Pre-excitation syndrome
  • QRS duration > 120 ms
  • Atrial Fibrillation or significant ventricular arrhythmia
  • Treatment with Digoxin
  • Pacemaker with 100% pacemaker dependence

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CAD statusone month follow up

The main goal of this registry will be to compare sensitivity, specificity, positive and negative predictive values of the HyperQ HFQRS analysis for detecting the presence of coronary artery disease to that of standard ECG analysis.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Minneapolis Heart Institute Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Cleveland Clinic Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

University of Virginia

๐Ÿ‡บ๐Ÿ‡ธ

Charlottesville, Virginia, United States

Minneapolis Heart Institute Foundation
๐Ÿ‡บ๐Ÿ‡ธMinneapolis, Minnesota, United States
Jo Anne Goldman, RT, RCIS, CCRC
Contact
612-863-3793
JoAnne.Goldman@allina.com
Rob Schwartz, MD
Contact
612-863-3823
robert.Schwartz@allina.com
Robert Schwartz, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.